Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.60 |
| ▸ | MC4R | P32245 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | CHKA | P35790 | 3/20 | 0.50 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29809149 | 1.00 | HRH3 (0.60) | HRH3MC4RFAAHDRD2CHKA | |
| SCHEMBL2227678 | 0.94 | HRH3 (0.62) | HRH3MC4RFAAHCHKA | |
| SCHEMBL20804353 | 0.92 | FAAH (0.63) | HRH3FAAHDRD2DRD3DRD4 | |
| SCHEMBL28024099 | 0.92 | FAAH (0.63) | HRH3FAAHDRD2DRD3DRD4 | |
| SCHEMBL12725366 | 0.91 | DRD2 (0.55) | HRH3MC4RFAAHDRD2CHKA | |
| SCHEMBL2227448 | 0.85 | HRH3 (0.60) | HRH3FAAH | |
| SCHEMBL27912351 | 0.85 | FAAH (0.56) | HRH3FAAHDRD2DRD3DRD4 | |
| SCHEMBL29678370 | 0.85 | HRH3 (0.60) | HRH3FAAH | |
| SCHEMBL27896883 | 0.85 | FAAH (0.54) | HRH3FAAHDRD2DRD3DRD4 | |
| SCHEMBL14661526 | 0.84 | HRH3 (0.60) | HRH3MC4RCHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805341-B | Aromatic heterocyclic compound, and preparation method and application thereof | 上海翊石医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022161420-A1 | CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| CN-114805341-A | Aromatic heterocyclic compounds and preparation method and application thereof | 上海翊石医药科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| EP-3322706-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-11-11 | — | — | EP | disclosed |
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| EP-2448582-B1 | QUINOLINE-8-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY | AGIOS PHARMACEUTICALS INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2017-04-06 | — | — | US | disclosed |
| WO-2017011776-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
| EP-2197854-A1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.r.l. (IT) | 2010-06-23 | — | — | EP | disclosed |
| EP-2049508-B1 | N-HYDROXY-3-(4-{3-PHENYL-3-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | DAC SRL (IT) | 2010-06-09 | — | — | EP | disclosed |
| US-20100113438-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2010-05-06 | — | — | US | disclosed |
| CN-101448802-A | N-hydroxy-3-(4-{3-phenyl-S-oxo-propenyl}-phenyl)-acrylamide derivatives and related compounds as histone deacetylase inhibitors for the treatment of cancer | DAC SRL (IT) | 2009-06-03 | — | — | CN | disclosed |
| EP-2049508-A2 | N-HYDROXY-3-(4-{3-PHENYL-3-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | DAC S.r.l. (IT) | 2009-04-22 | — | — | EP | disclosed |
| EP-2033956-A1 | A new class of histone deacetylase inhibitors | DAC S.r.l. (IT) | 2009-03-11 | — | — | EP | disclosed |
| WO-2009027395-A1 | A NEW CLASS OF HISTONE DEACETYLASE INHIBITORS | DAC S.R.L. (IT) | 2009-03-05 | — | — | WO | disclosed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
| WO-2007113249-A2 | N-HYDROXY-3-(4-{3-PHENYL-S-OXO-PROPENYL}-PHENYL)-ACRYLAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER | DAC S.R.L. (IT) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113438-A1 | CLASS OF HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC11 | HRH3 36/4885MC4R 2796/4885FAAH 670/4885 |
| US-20170096425-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | HRH3 1340/4885MC4R 1447/4885FAAH 4815/4885 |
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | HRH3 203/4885MC4R 2221/4885FAAH 4593/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | HRH3 203/4885MC4R 2221/4885FAAH 4593/4885 |
| US-20080269275-A1 | Novel Mchr1 Antagonists and Their Use for the Treatment of Mchr1 Mediated Conditions and Disorders | MCHR1, MCHR2, HCRTR1 | HRH3 116/4885MC4R 24/4885FAAH 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.